Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

l minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. A replay of the webcast will be archived on the Sunesis website for two weeks until March 25, 2008.

About Sunesis' Oncology Programs

Sunesis has built a portfolio of product candidates in oncology focused on inhibition of the cell-cycle and survival signaling. Our lead product candidate, SNS-595, is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. SNS-595 is a specific DNA intercalator and topoisomerase II poison, causing replication-dependent site-selective double-strand DNA damage, irreversible G2 arrest and rapid apoptosis. A Phase 2 single agent clinical trial of SNS-595 in ovarian cancer and a Phase 1b clinical trial of SNS-595 combination with cytarabine in relapsed/refractory AML are both ongoing. SNS-032, a potent and selective inhibitor of CDKs 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory CLL or multiple myeloma. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other protein kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information o
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced the next step in its ... bio-analytics solutions provider with the naming of current Chief ... Chief Executive Officer, while current Chairman of the Board ... serve as Chairman. These changes are effective January 1, ...
(Date:12/17/2014)... , Dec. 17, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, announced today its ... held in San Francisco, CA. ... Chief Executive Officer, will present on Monday, January 12, ... presentation will be webcast live and may be accessed ...
(Date:12/15/2014)... YORK , Dec. 15, 2014  GlassesOff Inc. ... Yuval Bar-Gil as an independent director of the ... founder of AeroScout and served as its CEO until ... in 2012, a $240 million transaction. Recognized as the ... Mr. Bar-Gil,s leadership, AeroScout provided Wi-Fi -based RFID solutions ...
(Date:12/13/2014)... , Dec. 12, 2014 /CNW/ - MaRS and Virgin ... today that they have joined forces to support Canadian entrepreneurs ... , Virgin Group Founder was at the MaRS Centre to ... new, national impact venture fund. This fund has $1 million ... Vancouver -based Mindset Social Innovation Foundation, founded ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... On June 27, 2008,GeneraMedix Inc. received approval ... its Epoprostenol for Injection 1.5 mg New Drug,Application ... indicated for the long-term,intravenous treatment of primary pulmonary ... of disease in NYHA,Class III and Class IV ...
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... the,discovery, development and commercialization of novel drugs ... respiratory diseases, today,announced that it was added ... Investment Group reconstituted its comprehensive set of ...
... July 3 Senesco,Technologies, Inc. ("Senesco" or the ... has contracted with Polyplus-transfection (Illkirch, France) to,supply Polyplus,s ... of siRNA against Factor 5A and a plasmid ... reported positive preclinical in vivo results,using its combination ...
Cached Biology Technology:GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg 2Advanced Life Sciences Added to Russell Microcap Index 2Advanced Life Sciences Added to Russell Microcap Index 3Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 2Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 3Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 4
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
(Date:11/15/2014)... 13, 2014  While we may still be a few ... in "Star Trek" to gain instant access to all that ... with smartphones and tablets for monitoring and measuring our health ... This may seem a tad Orwellian to some, but a ... of these technological opportunities into their healthcare regime. ...
(Date:11/7/2014)... Debra Auguste, associate professor, biomedical engineering, in the ... of New York, have identified a molecule that ... the most aggressive forms of breast cancer. , ... mortality rate owing to aggressive proliferation and metastasis ... Professor Auguste,s team, discovered the overexpression of intercellular ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... A team of researchers from the Hawai,i Institute ... map of corals and zooxanthellae as part of a ... provides global-scale biological and ecosystem information on symbiotic zooxanthellae ... that live inside the cells of other marine organisms ...
... University of Maryland School of Medicine researchers have uncovered ... understanding cardiac arrhythmia and other heart muscle problems. Understanding ... open the door to new treatments. The study, published ... electrical impulses that coordinate contraction in heart and skeletal ...
... Scientists are reporting the development and successful tests in humans ... from exhaled breath, an advance that they describe as a ... non-invasive test for MS -- the most common neurological disease ... ACS Chemical Neuroscience . Hossam Haick and colleagues report ...
Cached Biology News:An online global map of coral and zooxanthellae data for climate change study is released 2An online global map of coral and zooxanthellae data for climate change study is released 3UM School of Medicine finds new pathway critical to heart arrhythmia 2UM School of Medicine finds new pathway critical to heart arrhythmia 3Advance toward a breath test to diagnose multiple sclerosis 2
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... well Magnetic-Ring Stand is designed for paramagnetic ... microplates. The stand has a plastic base ... plate footprint. The use of 96 extremely ... easy magnetic separation. With this magnetic stand, ...
... DNA polymerase from Thermus aquaticus expressed in ... 1 tube of 250 units enzyme/tube and ... DNA), is the same enzyme as AmpliTaq ... a proprietary separation process to ensure that ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
Biology Products: